CHEMOMAB THERAP. ADR/20 (F:2QV0) — Market Cap & Net Worth
Market Cap & Net Worth: CHEMOMAB THERAP. ADR/20 (2QV0)
CHEMOMAB THERAP. ADR/20 (F:2QV0) has a market capitalization of $15.26 Million (€13.05 Million) as of June 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #25946 globally and #2240 in its home market, demonstrating a 269.81% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CHEMOMAB THERAP. ADR/20's stock price €2.94 by its total outstanding shares 20764300 (20.76 Million).
CHEMOMAB THERAP. ADR/20 Market Cap History: 2021 to 2025
CHEMOMAB THERAP. ADR/20's market capitalization history from 2021 to 2025. Data shows change from $134.73 Million to $71.37 Million (-31.86% CAGR).
CHEMOMAB THERAP. ADR/20 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CHEMOMAB THERAP. ADR/20's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 2QV0 by Market Capitalization
Companies near CHEMOMAB THERAP. ADR/20 in the global market cap rankings as of June 19, 2026.
Key companies related to CHEMOMAB THERAP. ADR/20 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
CHEMOMAB THERAP. ADR/20 Historical Marketcap From 2021 to 2025
Between 2021 and today, CHEMOMAB THERAP. ADR/20's market cap moved from $134.73 Million to $ 71.37 Million, with a yearly change of -31.86%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | €71.37 Million | +53.93% |
| 2024 | €46.37 Million | +320.70% |
| 2023 | €11.02 Million | -78.98% |
| 2022 | €52.44 Million | -61.08% |
| 2021 | €134.73 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of CHEMOMAB THERAP. ADR/20 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $15.26 Million USD |
| MoneyControl | $15.26 Million USD |
| MarketWatch | $15.26 Million USD |
| marketcap.company | $15.26 Million USD |
| Reuters | $15.26 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CHEMOMAB THERAP. ADR/20
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases in the United States. Its lead product candidate is Nebokitug, a humanized monoclonal antibody attenuates the basic function of CCL24 that has completed phase 2 clinical trial for the treatment of primary sclerosing ch… Read more